AbbVie Inc. took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, tax reform is the key to boosting U.S. manufacturing. The ...

Both issues could hurt AbbVie, but there's no need to worry too much at this point. None of the Trump administration's tariffs have afected AbbVie so far. That's because the across-the-board ...

Nearly everything looked great with AbbVie's (NYSE: ABBV) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune ...

TDP floor leader Kovelamudi Ravindra (Nani) is believed to be the front runner for the top post as Union minister Dr Pemmasani Chandrasekhar declared his name in the presence of corporators and ...

AbbVie Inc.’s (NYSE:ABBV) year is off to a very strong start. The company beat Q1 2025 revenue and EPS estimates and raised the full-year EPS guidance range by $0.10 and the full-year revenue ...

It beat convincingly on both the top and bottom lines. For its first quarter of this year, AbbVie's net revenue was $13.3 billion, representing a sturdy 8% improvement on a year-over-year basis.

North Chicago, Ill.: AbbVie has announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trenibotulinumtoxinE (TrenibotE) for the treatment of ...

Rob Stothard / Bloomberg via Getty Images AbbVie's first-quarter sales and adjusted earnings per share topped estimates. The drugmaker lifted its full-year adjusted EPS forecast by 10 cents.

Following Sudheer’s defection, five more YSRCP councillors crossed over to the TDP, narrowing the tally to 13 for the YSRCP and 11 for the TDP. Though the numbers still favour the YSRCP ...

AbbVie's first-quarter results improved with revenue growth powered by soaring sales for treatments in its immunology portfolio, prompting the company to raise its outlook for the year even as ...